Mineralys Therapeutics, Inc. (MLYS)

Market Cap	2.93B
Revenue (ttm)	n/a
Net Income (ttm)	-171.36M
Shares Out	79.14M
EPS (ttm)	-2.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,777,193
Open	36.24
Previous Close	36.04
Day's Range	36.22 - 37.82
52-Week Range	8.24 - 47.65
Beta	0.40
Analysts	Strong Buy
Price Target	46.40 (+25.3%)
Earnings Date	Nov 10, 2025

About MLYS

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 10, 2023
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: MLYS
• Website: https://mineralystx.com

Analyst Summary

According to 6 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $46.4, which is an increase of 25.30% from the latest price.

Price Target

$46.4

(25.30% upside)

Analyst Consensus: Strong Buy